According to H.C. Wainwright's Aug. 9, 2017 research report, Inovio Pharmaceuticals Inc. (INO:NASDAQ) exited Q2/17 with $92 million in cash. It has closed a public offering that yielded $70.5 million, which "would be used for general corporate purposes, including clinical trial expenses," according to Selvaraju. "We estimate that the company's pro forma cash position after the offering should be sufficient to fund at least 18 months of operations."
Inovio reported top-line quarterly revenues of $20.4 million, "handily beating our original projection of only $6.7M," wrote the analyst. "This was primarily driven by the recognition of $13.8M in revenue from MedImmune," Selvaraju explained. "This revenue recognition occurred upon MedImmune's definitive selection of a new cancer product candidate to be tested in clinical trials against an undisclosed cancer target from the two companies' ongoing research collaboration."
Selvaraju reminded investors of revenue expected from another corporate partnership, this one with ApolloBio, for development in China of Inovio's DNA-based, nonsurgical immunotherapy, VGX-3100. This deal "involves an upfront payment of $15M and an equity investment of $35M in Inovio common stock," he said.
The report also indicated patients are being recruited for REVEAL 1, a primary study, and REVEAL 2, a confirmatory study, of Inovio's VGX-3100 in the treatment of "HPV-16/18-related high-grade cervical dysplasia, or high-grade squamous intraepithelial lesions," Selvaraju wrote. "Each study is slated to enroll 198 patients in over 100 centers globally."
Selvaraju outlined the market timing and potential for commercialization of VGX-3100. "We currently project that the REVEAL program would take two years to complete and VGX-3100 could enter the market in late 2020, with peak global sales of approximately $1.2B in 2030," he said.
H.C. Wainwright reiterated its Buy rating and 12-month price target of $13 per share on Inovio. The stock is currently trading at around $5.43 per share.
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: none. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Inovio Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from H.C. Wainwright & Co., Earnings Update, Aug. 9, 2017
I, Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D. CFA , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Inovio Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of July 31, 2017 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Inovio Pharmaceuticals, Inc.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The Firm or its affiliates did receive compensation from Inovio Pharmaceuticals, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in Inovio Pharmaceuticals, Inc. as of the date of this research report.